Stratification of SNOT-22 scores into mild, moderate or severe and relationship with other subjective instruments

Toma, Shamim; Hopkins, Claire

doi:10.4193/rhino15.072

Cited by 94 publications

(63 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Disposition of patients is illustrated in Figure3.Of the 67 enrolled patients, 35 (52.2%) were male and 37 (55.2%) were diagnosed with bilateral nasal polyps by endoscopy, each representing approximately half the patients in each study arm. All patients reported moderateto-severe CRS symptoms17 at baseline, with a mean ± standard deviation SNOT-22 score of 68.2 ± 18.4 (range, 25-107) and a 4CS score of 9.7 ± 1.59 (range, 7-12). In addition, all patients exhibited sinonasal inflammation based on their baseline Zinreich scores (mean, 20.3 ± 12.3 [median 17; range, 1-53]).…”

mentioning

confidence: 99%

Long‐acting implantable corticosteroid matrix for chronic rhinosinusitis: Results of LANTERN Phase 2 randomized controlled study

Cervin

Rimmer

Wróbel

et al. 2021

Int Forum Allergy Rhinol

View full text Add to dashboard Cite

Background: Topical steroids are first-line treatment for chronic rhinosinusitis (CRS), but fail to provide adequate symptom control for all patients. Designed for medical treatment failures, LYR-210 is an implantable matrix that locally elutes mometasone furoate to inflamed sinonasal tissue for up to 24 weeks in CRS patients. In an open-label phase 1 study, LYR-210 demonstrated clinically relevant improvement in the 22-item Sino-Nasal Outcome Test (SNOT-22). Safety and efficacy of LYR-210 in CRS were evaluated in the LANTERN Phase 2 study. Methods: Sixty-seven surgically naive adult CRS patients who were inadequately controlled by previous medical management and seeking an alternative treatment enrolled in a multicenter, blinded, controlled, dose-ranging study. Patients had moderate-to-severe disease based on SNOT-22 and composite 7-day average scores of the 4 cardinal CRS symptoms (4CS), with diagnosis confirmed by nasal endoscopy and magnetic resonance imaging. Patients were randomized (1:1:1) to saline irrigation-only control or bilateral in-office administration of LYR-210 (2500 µg) or LYR-210 (7500 µg). Safety and efficacy were evaluated over 24 weeks. Results: Both LYR-210 doses were safe and well-tolerated over the 24-week treatment period. LYR-210 demonstrated rapid and durable dose-dependent symptom improvement based on 4CS and SNOT-22, with LYR-210 (7500 µg) achieving statistical significance as early as 8 weeks and out to 24 weeks compared with control. LYR-210 (7500 µg) reduced rescue treatment use and radiographic ethmoid opacification at week 24.

show abstract

mentioning

confidence: 99%

Long‐acting implantable corticosteroid matrix for chronic rhinosinusitis: Results of LANTERN Phase 2 randomized controlled study

Cervin

Rimmer

Wróbel

et al. 2021

Int Forum Allergy Rhinol

View full text Add to dashboard Cite

show abstract

“…The final dataset included SNOT‐22 results from 800 CRS patients. The mean ± SD total SNOT‐22 score of these patients was 36.2 ± 21.9, thus representing a CRS cohort with, on average, moderate disease severity 36 . The overall proportion of No problem responses ranged from 16% to 76%; Very mild problem ranged from 10% to 27%; Mild or slight problem ranged from 6% to 20%; Moderate problem ranged from 5% to 26%; Severe problem ranged from 2% to 21%; and Problem as bad as it can be ranged from 1% to 12%.…”

Section: Resultsmentioning

confidence: 99%

Exploring possibilities for shortening the 22‐item Sino‐Nasal Outcome Test (SNOT‐22) using item response theory

Liu

Phillips

Speth

et al. 2021

Int Forum Allergy Rhinol

View full text Add to dashboard Cite

Background: Even with a high-quality instrument, such as the 22-item Sino-Nasal Outcome Test , patients can be overwhelmed by repeated completion of questionnaires, leading to nonadherence and reduced data quality. The aim of this study was to evaluate whether the SNOT-22 could be made more concise without losing the valuable information that it provides.Methods: A modern psychometric approach, item response theory (IRT), was used on a sample of 800 patients with chronic rhinosinusitis (CRS). The SNOT-22 was refined based on: (1) the item information criteria, retaining only items with above-average information; and (2) the total test information, retaining only the most discriminating items to cover at least 30% of the information within each subdomain. The preliminary validity and reliability of these refined scales were assessed using Cronbach's alpha and Pearson's correlation.Results: Using an IRT approach, we find that it may be possible to shorten the SNOT-22 to an 11-item and six-item version based on psychometric properties.Item information functions of the shortened 11-item and six-item scales demonstrate that both versions accurately covered the CRS symptom-severity continuum. Preliminary reliability and validity analysis showed that both refined scales had good to excellent reliability (Cronbach's alpha ≥ 0.80) and were highly associated with the original full-length scale (r ≥ 0.90). Conclusion:IRT provides data-driven opportunities for the continuous development and refinement of the SNOT-22. While patient and provider input must be accounted for too, our results show that future revisions of the SNOT-22 could include significantly fewer items.

show abstract

“…Higher scores indicate a greater rhinosinusitis‐related health burden, 22 , 23 with classifications of mild disease based on scores of 8–17, moderate 22.5–48, and severe 54–83. 24 …”

Section: Methodsmentioning

confidence: 99%

“…27 Due to multiple comparisons, a Bonferroni correction was applied and the significance level was set at p < .003. Difference between classifications of SNOT‐22 total scores (mild, moderate, and severe), 24 sputum color (mucoid, mucopurulent, and purulent), presence or absence of Pseudomonas aeruginosa colonization, and classifications of bronchiectasis severity (based on BSI) were analyzed using Chi square. Statistical significance was set at an α < .05 unless otherwise stated.…”

Section: Methodsmentioning

confidence: 99%

The clinical impact of self‐reported symptoms of chronic rhinosinusitis in people with bronchiectasis

Lee

Nicolson

Bondarenko

et al. 2021

Immunity Inflam & Disease

View full text Add to dashboard Cite

Background: Chronic rhinosinusitis affects 62% of adults with bronchiectasis and is linked to greater bronchiectasis severity. However, the impact of symptoms of chronic rhinosinusitis on disease-specific and cough-related quality of life is unknown. Methods:In this cross-sectional study, adults with stable bronchiectasis and chronic rhinosinusitis symptoms completed the sinonasal outcome test-22 (SNOT-22), quality of life-bronchiectasis questionnaire, and Leicester cough questionnaire. Bronchiectasis severity was assessed using the bronchiectasis severity index (BSI) and chest high-resolution computed tomography (HRCT).Results: Sixty participants with bronchiectasis (mean [SD] forced expiratory volume in 1 s of 73.2 [25.5] %predicted) were included. Greater severity of chronic rhinosinusitis symptoms (based on SNOT-22) was moderately associated with impaired cough-related quality of life (according to the Leicester cough questionnaire; all r > −.60) and impaired bronchiectasis-specific quality of life (based on the quality of life-bronchiectasis questionnaire), with impaired physical function (r = −.518), less vitality (r = −.631), reduced social function (r = −.546), greater treatment burden (r = −.411), and increased severity of respiratory symptoms (r = −.534). Chronic rhinosinusitis symptoms were unrelated to disease severity according to the BSI (r = .135) and HRCT scoring (all r < .200). The severity of chronic rhinosinusitis symptoms was not affected by sputum color (p = .417) or the presence of Pseudomonas aeruginosa colonization (p = .73). Conclusions: In adults with bronchiectasis, chronic rhinosinusitis has a consistent and negative impact on both cough-related and bronchiectasisspecific quality of life.

show abstract

Stratification of SNOT-22 scores into mild, moderate or severe and relationship with other subjective instruments

Cited by 94 publications

References 5 publications

Long‐acting implantable corticosteroid matrix for chronic rhinosinusitis: Results of LANTERN Phase 2 randomized controlled study

Long‐acting implantable corticosteroid matrix for chronic rhinosinusitis: Results of LANTERN Phase 2 randomized controlled study

Exploring possibilities for shortening the 22‐item Sino‐Nasal Outcome Test (SNOT‐22) using item response theory

The clinical impact of self‐reported symptoms of chronic rhinosinusitis in people with bronchiectasis

Contact Info

Product

Resources

About